AR-Aid Patient Management Tool
In the clinical trial,
IT IS IMPORTANT TO RECOGNIZE AND INITIATE TREATMENT
FOR
DIFFERENTIATION SYNDROME
Symptoms of differentiation syndrome occurred in 14% (n=29/214) of patients treated with IDHIFA®.
Download our IDHIFA® wallet cards, printable cards for patients and caregivers to show to their non-regular healthcare providers. These printable resources also include information about differentiation syndrome and other ARs associated with IDHIFA®.
IDHIFA® Wallet Cards
In the clinical trial,
Differentiation syndrome* reported in patients with R/R AML
All grades |
≥Grade 3 |
---|---|
29 (14) |
15 (7) |
*Differentiation syndrome can be associated with other commonly reported events such as respiratory failure, dyspnea, hypoxia, pyrexia, peripheral edema, rash, or renal insufficiency.
ADDITIONAL ANALYSIS: Frequency of differentiation syndrome over time1
Differentiation syndrome has been observed with and without concomitant hyperleukocytosis in as early as 1 day and up to 5 months after IDHIFA® initiation.
Download our IDHIFA® wallet cards, printable cards for patients and caregivers to show to their non-regular healthcare providers. These printable resources also include information about differentiation syndrome and other ARs associated with IDHIFA®.
IDHIFA® Wallet Cards
MONITOR YOUR PATIENTS: Differentiation syndrome may occur with IDHIFA®
Differentiation syndrome is associated with rapid proliferation and differentiation of myeloid cells and may be life-threatening or fatal if not treated; recognizing and initiating management of this condition is important.
Initial management |
|
---|---|
|
Subsequent management |
|
---|---|
|
|
|
|
|
aGrade 2 is moderate.
IDHIFA® has a terminal half-life of 7.9 days and a mean total body clearance of (CL/F) of 0.70 L/hour (CV% 62.5).
Download our IDHIFA® wallet cards, printable cards for patients and caregivers to show to their non-regular healthcare providers. These printable resources also include information about differentiation syndrome and other ARs associated with IDHIFA®.
IDHIFA® Wallet Cards
Eligibility
Patients must meet the following criteria to enroll:
Program Benefits
Program Timing
Additional Terms and Conditions of the Celgene Commercial Co-pay Programs
© 2017 Celgene Corporation 06/17 US-CELG170216
This site is intended for U.S. audiences only.